Drugs / Fluorouracil (5-FU)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT07660120 | Jul 2026 → Jul 2027 expected | reactive cutaneous fibrous lesion | University of California, Davis | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01274624 Background | Dec 2010 → Feb 2018 | colorectal cancer | Oncolytics Biotech | Completed | Met primary |
Press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorouracil (5-FU) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660120 ↗ |
| Known as | 5-fluorouracil | “Another medication, called 5-fluorouracil (5-FU), has been shown in prior studies to work well when combined with steroids, but it is usually given by injection, which can be...” NCT07660120 ↗ |
| Route | Intravenous | “400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.” NCT01274624 ↗ |